Evidence map›Paper›PMID 42394399›Full record

ReviewAlimentary pharmacology & therapeutics2026

Review Article: Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine.

Yule Ma, Huigang Li, Huan Chen, Jinxin Xu, Ziyi Ye, Yuhang Li, Xiang Wu, Jinyan Chen, Chenghao Cao, Peiru Zhang and 7 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yule MaSchool of Clinical Medicine, Hangzhou Medical College, Hangzhou, China.
Huigang LiInstitute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China.ORCID https://orcid.org/0000-0002-5575-8068
Huan ChenQingdao Medical College of Qingdao University, Qingdao, China.
Jinxin XuThe Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Ziyi YeSchool of Clinical Medicine, Hangzhou Medical College, Hangzhou, China.
Yuhang LiInstitute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China.
Xiang WuNingbo University School of Medicine, Ningbo University, Ningbo, China.ORCID https://orcid.org/0000-0002-2134-1184
Jinyan ChenInstitute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China.
Chenghao CaoInstitute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China.
Peiru ZhangThe Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Ruijie ZhaoChu Kochen Honors College of Zhejiang University, Hangzhou, China.
Jun LiSchool of Basic Medicine and Forensic Science, Hangzhou Medical College, Hangzhou, China.
Cheng ZhuThe Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Jianyong ZhuoHepatobiliary Center and Transplantation Center, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
Shengjun XuDepartment of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.ORCID https://orcid.org/0000-0002-1679-1885
Xiao XuHepatobiliary Center and Transplantation Center, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0002-2761-2811
Di LuGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China.ORCID https://orcid.org/0000-0002-8724-3739

Funding

Key Research and Development Program of Zhejiang Province 2024C03051the Innovation Team, Hangzhou Medical College CXLJ202401the National Natural Science Foundation of China 82303387the Ningbo Top Medical and Health Research Program 2024020818the Special Support Program for Research Institutes of Zhejiang Province YS202602
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. For eligible patients, liver transplantation is a curative treatment option, but recurrence after transplantation can severely affect long-term survival rates. Reliable biomarkers are urgently needed to optimise the entire transplantation process.

aimsThis review aims to summarize the role of traditional and emerging biomarkers in the treatment of HCC with liver transplantation, discuss the current challenges, and explore the direction of development in precision medicine.

methodWe conducted a review of recent literature on protein biomarkers, genomic feature profiles, transcriptomic and proteomic markers, as well as the application of liquid biopsies in HCC liver transplantation.

resultsTraditional biomarkers (including alpha-fetoprotein, its fucosylated variant AFP-L3, and protein induced by vitamin K absence or antagonism II) are widely used for recipient screening, staging, and recurrence prediction. Emerging multi-omics markers and liquid biopsy markers provide deeper molecular insights and enable non-invasive real-time monitoring. They assist in pre-transplant risk stratification, downstaging response assessment, early recurrence detection, and guidance of personalised immunosuppression and adjuvant therapy.

conclusionBiomarkers are the core tools for precision medicine in liver transplantation for HCC. Despite challenges in standardization and clinical application, combining traditional biomarkers with multi-omics and liquid biopsy technologies holds promise for further improving patient prognosis.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularLiver NeoplasmsLiver TransplantationPrecision MedicineBiomarkersHumansNeoplasm Recurrence, LocalProteomicsBiomarkersBiomarkers, Tumorbiomarkershepatocellular carcinomaliver transplantationprecision medicineprognosis

Identifiers

PMID42394399
PMCPMC13419122

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.